帕博利珠单抗治疗美国持续性、复发性或转移性宫颈癌的成本效果分析
本研究基于KEYNOTE-826三期随机试验数据,构建30年分区生存模型,从美国医疗支付方角度比较帕博利珠单抗与安慰剂治疗持续性、复发性或转移性宫颈癌的成本与效果。意向治疗人群的ICER为247,663美元/QALY,概率敏感性分析显示在当前150,000美元/QALY支付阈值下帕博利珠单抗具有成本效果的概率为零。结论认为按当前价格加用帕博利珠单抗费用高昂,可能不具有成本效果。
要点
- 意向治疗人群帕博利珠单抗较安慰剂增加0.74 QALY,额外成本182,271美元,ICER为247,663美元/QALY。
- PD-L1 CPS≥1和≥10人群的ICER分别为253,322美元/QALY和214,212美元/QALY。
- 当前150,000美元/QALY支付阈值下帕博利珠单抗具有成本效果的概率为零。
核心结论
- 按当前美国价格,在化疗基础上加用帕博利珠单抗费用高昂,对持续性、复发性或转移性宫颈癌可能不具有成本效果。
研究设计与样本
- 基于KEYNOTE-826三期随机试验临床数据,构建30年终身 horizon 的分区生存模型,从美国医疗支付方角度比较帕博利珠单抗与安慰剂的成本与效果。
主要发现
- 意向治疗人群帕博利珠单抗较安慰剂增加0.74 QALY,额外成本182,271美元,ICER为247,663美元/QALY。
- PD-L1 CPS≥1人群ICER为253,322美元/QALY,CPS≥10人群ICER为214,212美元/QALY。
- 单因素敏感性分析显示帕博利珠单抗对ICER影响最大。
- 概率敏感性分析显示当前150,000美元/QALY支付阈值下帕博利珠单抗具有成本效果的概率为零。
- 帕博利珠单抗价格至少需降至28.336美元(当前价格的55.8%)才有50%概率具有成本效果。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The effectiveness of pembrolizumab for persistent, recurrent, or metastatic cervical cancer has been demonstrated. We aimed to evaluate its cost-effectiveness from the United States (US) healthcare payers perspective. METHODS: A partitioned survival model over a 30-year lifetime horizon was developed to compare the cost and effectiveness of pembrolizumab versus placebo based on clinical data from the KEYNOTE-826 phase 3 randomized trial. Costs and health state utilities were obtained from literature and publicly available databases. The incremental cost-effectiveness ratio (ICER) was measured. One-way and probabilistic sensitivity analyses were conducted. RESULTS: For the Intention-to-Treat patients, pembrolizumab was associated with an additional 0.74 quality-adjusted life-year (QALY) at an additional cost of $182,271 when compared with placebo. The ICER was $247,663/QALY. For patients with a programmed death-ligand 1 combined positive score ≥ 1 and 10, the ICER was $253,322/QALY and $214,212/QALY, respectively. One-way sensitivity analyses showed that pembrolizumab had the greatest impact on the ICER. Probabilistic sensitivity analyses showed that the probability of pembrolizumab being cost-effective was zero at the current willingness-to-pay threshold of $150,000/QALY. The price of pembrolizumab had to reduce at least to $28.336 (55.8% of the current price) for it to be cost-effective in a 50% of chance. CONCLUSION: The addition of pembrolizumab to chemotherapy is costly and might not be cost-effective for persistent, recurrent, or metastatic cervical cancer at the current price in the US.
引用
- Shi Y, Chen J, Shi B, et al. Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer. Gynecol Oncol. 2021. PMID: 34920886. doi:10.1016/j.ygyno.2021.12.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。